May 23, 2017
Selexis and OSE Immunotherapeutics in commercial agreement
Selexis SA and OSE Immunotherapeutics have signed a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform.